Defendant
6 cases as defendant.
I'll research this company now.
Aurobindo Pharma USA, Inc. ("Aurobindo USA") is the U.S. subsidiary of Aurobindo Pharma Limited, an Indian multinational headquartered in Hyderabad (NSE: AUROPHARMA; BSE: 524804). The U.S. entity is headquartered in East Windsor, New Jersey, and was established in the early 1990s (sources cite 1992 or 1994). It is wholly owned by the parent. Parent-level scale is well documented: FY2026 (year ended March 2026) consolidated revenue of about ₹33,653 crore, roughly 40,000 employees, and a market capitalization around ₹91,700 crore. The parent reports the U.S. as its largest market (~43% of revenue). Entity-level headcount and revenue for Aurobindo USA are not disclosed; third-party aggregators give inconsistent figures (roughly 500–1,000+ employees, revenue estimates ranging from $50M to $1B), which should be treated as unverified.
Operations. Aurobindo USA is an operating generics business, not an NPE. Its U.S. commercial and manufacturing footprint spans several affiliates: oral solid generics (Aurobindo USA), injectables (Auromedics), private-label OTC (Aurohealth), branded nutraceuticals (Natrol), controlled substances and U.S. R&D/manufacturing (Aurolife Pharma, incl. a Raleigh, North Carolina facility), and specialty/oncology and injectables under Eugia. The parent also makes active pharmaceutical ingredients (including penicillin-G), and is expanding into biosimilars (CuraTeQ) and complex inhalation products. It reported roughly 596 cumulative U.S. FDA ANDA approvals as of September 2026, and acquired Lannett Company for about $250 million (2026), launching a generic Advair Diskus.
Litigation posture. Aurobindo USA appears in the tracked data only as a defendant (2 cases, 0 as plaintiff) — the profile of an operating company defending Hatch-Waxman ANDA suits rather than a patent assertion entity. Both tracked matters are in the District of Delaware, not a plaintiff-friendly venue like the Eastern District of Texas.
Notable cases. Merck KGaA et al. v. Aurobindo Pharma USA, Inc. et al. (D. Del., No. 1:23-cv-00039) and Merck KGaA et al. v. Hopewell Pharma Ventures, Inc. et al. (D. Del., No. 1:22-cv-01365, filed Oct. 17, 2022) were brought by Merck KGaA, Merck Serono S.A., and Ares Trading S.A. against ANDA filers. The asserted patents (e.g., U.S. 8,377,903 and 10,849,919) cover cladribine dosing regimens for Mavenclad (multiple sclerosis); the '919 patent was later dropped from the case. Co-defendant Hopewell filed IPR petitions (IPR2023-00481/00482).
Original complaint asserted '919; plaintiffs ceased asserting the '919 patent against all defendants. The consolidated case was later globally stayed pending IPR appeals on the '947 and '903 patents.
Celgene sued Aurobindo entities in D.N.J. (2:20-cv-00315), asserting U.S. 7,855,217 among other patents. The case settled on July 15, 2021, and terminated July 19, 2021 (ANDA No. 213885).
Hatch-Waxman ANDA litigation. The '427 was expressly named among the patents-in-suit, but Celgene withdrew its '427 infringement claims. Consolidated/coordinated for claim construction with 17-cv-03159. Case terminated 2021-08-19.
D. Del. action asserting the '725 patent against Aurobindo; listed in some databases under Cipla. Settled/terminated.
Lilly filed a petition against Aurobindo (along with Lupin) on November 24, 2008, in the Cymbalta/duloxetine HCl ANDA litigation involving US 5,023,269. The case was resolved by the April 27, 2011 order/dismissals (docket not confirmed).
Consolidated into 22-1365. The '919 patent was asserted in the original complaint but dropped; the consolidated case involved the '947 and '903 patents.